eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Switching To And From Eliquis (Apixaban)

Switching from a VKA to ELIQUIS1

desk-img mob-img

Adapted from ELIQUIS SmPC.1

Switching from aspirin to ELIQUIS in patients with NVAF1

EHRA guidelines provide guidance on switching from aspirin to a NOAC for patients with NVAF.2

desk-img mob-img

Adapted from ELIQUIS SmPC.1
*The NOAC can be started immediately and aspirin stopped, unless combination therapy is deemed necessary despite the increased bleeding risk of the association.2

  • Aspirin switching will not be appropriate for all patients; for example, when aspirin is specifically indicated for other comorbidities or where VKA / NOACs are contraindicated. Switching from aspirin to ELIQUIS is at the discretion of the patient’s clinician.
  • Some patients may require combination therapy with an antiplatelet agent. The concomitant use of ELIQUIS with antiplatelet agents increases the risk of bleeding.1

Any prescribing decision should only be made by the prescribing healthcare professional on the basis of sound clinical reasons and after appropriate assessment with patient involvement in the


ELIQUIS is available for your patients with NVAF1

ELIQUIS is available for your patients with

View information to assist your daily practice, including adverse reactions, contraindications and interactions

ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily   
DVT = Deep Vein Thrombosis   
EHRA = European Heart Rhythm Association   
INR = International Normalised Ratio   
NOAC = Non-vitamin K antagonist Oral Anticoagulant
NVAF = Non-Valvular Atrial Fibrillation   
OD = Once Daily
PE = Pulmonary Embolism   
SmPC = Summary of Product Characteristics   
VKA = Vitamin K Antagonist


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Steffel J et al. Eur Heart J 2018; 00:1–64.